Centessa Pharmaceuticals plc announced new compensation terms for Dr. Saurabh Saha following his transition from Chief Executive Officer to advisor. Under the new agreement, Dr. Saha will provide advisory services at an hourly rate of $376, with reimbursement for business expenses. He will receive vesting of equity grants scheduled to vest on or before February 2, 2026, while equity due to vest after that date will be forfeited. Vested equity awards may be exercised for up to three months after the advisory agreement ends. Additionally, subject to Compensation Committee approval, Dr. Saha is eligible for a bonus equal to 100% of his target bonus for 2025 and continued participation in company benefit plans. These terms replace any previous severance or noncompetition benefits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-051424), on February 13, 2026, and is solely responsible for the information contained therein.